An Open-label, Randomised, Single-dose, Multi-cohort, Crossover Bioavailability Study of a Solution Formulation and Three Capsule Formulations of GSK2190915 in Healthy Adult Subjects Followed by a Repeat-dose, Randomized, Parallel Group, Double-blinded Study of One Selected Capsule Formulation and Matched Placebo in Elderly Healthy Subjects
Latest Information Update: 05 Sep 2023
At a glance
- Drugs Fiboflapon (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
Most Recent Events
- 28 Aug 2014 New trial record